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Community prevention of status
Epilepsy safety
Intellectual disabilitiesa b s t r a c t
Background: Oro-mucosal midazolam maleate (OMM) with suitable training to family and carers is being
increasingly recognized as the treatment of choice to mitigate the development of status epilepticus in
non-hospital community settings. There are no studies to describe the use, effectiveness, and suitable
dosing of OMM in adults with epilepsy in community settings.
Purpose: To describe the use, effectiveness, and dosing of OMM in the emergency treatment of epileptic
seizures in community settings.
Methods: A retrospective observational study (2016–17) design was used with participant recruitment
from four UK NHS secondary care outpatient clinics providing epilepsy management. Study sample
was of adult people with epilepsy (PWE) having had a recent seizure requiring OMM. Data on patient
demographics, patient care plans, details of a recent seizure requiring emergency medication, and dose
of OMM were collected from medical records.
Results: Study data from 146 PWE were included. The mean age of PWE was 41.0 years (SD 15.2) and
mean weight was 64.8Kg (SD 18.2). Fifty-three percent of PWE were recorded as having intellectual dis-
ability. The most frequently used concomitant medications were lamotrigine (43%). The majority of sei-
zures occurred at people’s homes (n = 92, 63%). OMM was most often administered by family/
professional care-givers (n = 75, 48.4%). Generalized (tonic/clonic) seizures were recorded in most people
(n = 106, 72.6%). The most common initial dose of OMM was 10 mg (n = 124, 84.9%). The mean time to
seizure cessation after administration of this initial dose was 5.5 minutes (SD = 4.5, Median 5.0, IQR
2.1–5.0). Only a minority of seizures led to ambulance callouts (n = 18, 12.3%) or hospital admissions
(n = 13, 9%).
Conclusion: This is the first observational study describing the use and effectiveness of OMM in adults in
community settings. Minimal hospital admissions were reported in this cohort and the treatment was
effective in ending seizures in adults in community settings.
 2021 Elsevier Inc. All rights reserved.1. Introduction
Prolonged seizures and status epilepticus are neurological
emergencies that pose a significant risk of morbidity and mortality[1]. Benzodiazepines are widely used as first line as rescue medica-
tions for prolonged seizures because of their efficacy and rapid
onset of action [2]. Midazolam, a benzodiazepine derivative can
be administered through different routes (oral/oromucosal, rectal,
nasal, intramuscular and intravenous) [3–5]. Studies comparing
the efficacy of midazolam have observed that nasal and oromu-
cosal routes are non-inferior andmore acceptable than intravenous
or rectal routes of administration in community settings [6–9].
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muscular midazolam are most effective; however, similar compar-
ative clinical studies on the effectiveness of oromucosal midazolam
maleate (OMM) are lacking [10]. Several studies have evaluated
the effectiveness of midazolam in children as the incidence of epi-
lepsy and status epilepticus is much more common in this popula-
tion than in adults [11–13]. Though the use of OMM has been
studied in adults generally there has be no systemic in adults with
epilepsy in non-hospital community settings [14].
The aim of this study was to describe the most common dose of
OMM used to treat adults with epilepsy and evaluate its effective-
ness in community settings.Fig. 1. Distribution of participant age at the time of most recent seizure.
2. Methods
This retrospective, observational, cross-sectional study, using
the STROBE guidance was done in 2016–17. It was conducted in
four NHS (National Health Service, UK) secondary care centers pro-
viding services for treatment and management of people with epi-
lepsy in the UK community. This study received a favorable ethical
opinion from the East Midlands - Nottingham Research Ethics
Committee (reference: 15/EM/0492), and was approved by the
local research and development department of each participating
trust/health board.
The inclusion criteria for this study were: [1] Participants aged
18 years or greater at time of most recent seizure requiring emer-
gency treatment [2] Participants with written patient care plans for
administration of OMM (Epistatus, Veriton Pharma Limited, UK)
as rescue medication for seizure.
Eligible participants were identified retrospectively from medi-
cal records. In order to minimize selection bias, participants were
selected in reverse consecutive order from the date they were last
seen for an out-patient appointment until the center’s recruitment
target had been achieved. To describe the use of OMM in commu-
nity settings (‘‘real life”), data on each person’s most recent episode
of a seizure requiring emergency medication were used for this
study. Data collected included: participant demographics, duration
and type of seizure, administered dose of OMM, time to cessation
of seizure, and need for ambulance call out or subsequent hospital
admission. Data were extracted from clinical records by members
of the direct care team to maintain patient confidentiality. Data
were forwarded to the research team after anonymization. Statisti-
cal analysis was performed using Microsoft Excel, using available
results with no imputation of missing data. Quantitative variablesFig. 2. Distribution of seizure frequency in the
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were presented as mean (standard deviation [S.D]) or median (in-
terquartile range [IQR]) and categorical data are presented as fre-
quency percentage. A sample size of 120–200 was chosen to
ensure reliability and precision in estimating the most common
dose of OMM, in line with similar studies.3. Results
3.1. Patient characteristics
Data from medical records of a total of 146 participants were
included in the study (81/146, 55% were male). Fig. 1 describes that
the mean age of participants at the time of the most recent seizure
when OMM was administered was 41.0 years (S.D. = 15.2).
The mean body weight of these patients, at the time of most
recent seizure was 64.8 Kg (S.D. = 18.2, range 30 kg to 110Kg, avail-
able for 71, 48.6%). Intellectual disability was the most common
comorbidity (77/146, 52.7%). The most commonly used concomi-
tant medications were lamotrigine (63, 43%), levetiracetam (60,
41%) and sodium valproate (53, 36%). Participants’ recent seizure
frequency at the time of the rescue medication use is described
in Fig. 2.
The most common location for administration of OMM was
recorded as home (92, 63.0%). The drug was most often adminis-
tered by a professional care-giver (75, 48.4%). Generalized tonic-
clonic seizure was the most common type of seizure treatment
with rescue medication (106, 72.6% Table 1).year preceding the date of data collection.
Fig. 3. Distribution of initial dose of OMM administered during most recent seizure.
Table 1
Distribution of types of seizure and cumulative dose of OMM administered.
Type of Seizure No. of patients % (n = 146) Mean cumulative dose (mg) SD
Generalized seizure (Tonic/Clonic) 106 72.6% 10.3 3.5
Focal seizure 19 13.0% 9.7 1.1
Myoclonus 4 2.7% 10 0.0
Other 2 1.4% 7.5 3.5
Not recorded 15 10.3% 11.3 3.5
Total 146 10.3 3.3
Table 3
Ambulance call outs and hospital admissions following OMM administration.






Not known 13 9%
Total 146




Admitted to ED or Acute Admissions Unit (following
ambulance call out)
10 7%
No admission 129 88%
Not known 7 5%
Total 146
*Of 13 call outs, medications administered were recorded in 3 patients: one had an
unknown dose of midazolam, one given 5 mg of oromucosal midazolam maleate
and an unknown dose of diazepam; one was given 5 mg of oromucosal midazolam
maleate (these doses are not represented in previous tables).** Hospital medica-
tions were recorded in four admitted patients: one given unknown dose of IV lor-
azepam plus an unknown dose of levetiracetam, one given an unknown dose of
paraldehyde, one given an unknown dose of phenytoin, one given 3 mg of lor-
azepam plus 1 g of phenytoin.
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The most common initial dose of OMM administered to partic-
ipants was 10 mg. This was used for 84.9% (n = 124) of seizures
recorded in this study. The distribution of initial doses of OMM is
shown in Fig. 3. Use of an initial dose of five mg was reported for
9.6% (n = 14) of seizure episodes. The mean cumulative dose
recorded for this patient cohort was 10.3 mg (S.D = 3.3 mg, range
of 5 to 35 mg, Table 1). The mean cumulative dose of OMM admin-
istered according to type of seizure is described in Table 1.
The mean length of time until cessation of seizure was 17.9
minutes (n = 4, S.D = 11.8, Median 19.8, IQR 13.3–24.4) following
a 5-mg dose of OMM and 5.5 minutes (n = 38, S.D = 4.5, Median
5.0, IQR 2.1–5.0) following a 10-mg dose of OMM.Table 2
Distribution of OMM dose according to duration and frequency of seizures in the year
preceding data collection (as prescribed in individual patient care plans).
Usual duration of seizure
(min)





0 to 2 40 10.32 2.70
2 to 4 58 9.64 2.31
4 to 6 58 10.29 1.83
6 to 8 4 11.67 2.58
8 to 10 2 12.50 5.00
10+ 32 9.64 2.09
Cluster seizures 4 10.00 -
Not known 22 8.57 3.06
Seizure frequency (No. per
month)
No. of patients Mean dose
(mg)
SD
0 to 2 43 9.36 2.11
0 to 3 31 9.10 1.94
7 to 10 10 10.77 1.88
11 to 20 10 10.59 1.66
over 20 27 10.33 2.90
Not known 25 11.11 2.11
*Total N numbers reflect patients who were given more than one seizure care
protocol.
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Time to cessation of seizure was not recorded for 71.2%
(n = 104) of participants. An initial dose of OMM was sufficient to
achieve cessation of seizure in 82.9% (n = 124) of participants,
while 10 participants required additional doses (data were
unavailable for 12 remaining participants).
The mean prescribed dose of OMM in patient care plans (for all
types of seizures) was 10.0 mg (S.D. = 2.3). Mean prescribed dose
according to seizure frequency and duration is shown in Table 2.
An initial dose of 10 mg was administered in 65.5% (n = 19/29)
with body weights between 30Kg and 60 kg and in 83.3%
(n = 35/42) with body weights ranging from 60 kg to 110Kg.
Seizures requiring post rescue medication ambulance call outs
was 9% (n = 13/146) three of four of whom required hospital
admission (7%, 10/146). Further details about these participants
are described in Table 3.4. Discussion
This retrospective observational study on the use of OMM in
adults with epilepsy in community settings shows that a 10-mg
dose of OMM was well tolerated and usually effective in achieving
seizure cessation. The demographics of our study population and
the high prevalence of generalized tonic/clonic seizures are consis-
tent with previous reports [15].
A 10-mg dose of OMM was effective in ending seizures within
an average of 5.5 minutes (Median 5.0) in our study sample.
This is consistent with previous observations on the rapid onset
of action and relatively short half-life of OMM [3,16]. Most partic-
ipants who received an initial 10-mg dose of OMM reported sei-
zure cessation. However, since time to cessation of seizure
following first dose of OMM was recorded for only 28.8% of
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data may be needed to confirm this result. Larger patient cohorts
are also needed to evaluate the relationship between patient char-
acteristics such as age, body mass index, and midazolam dose
responsiveness.
It is worth noting that our study population was comprised of a
large number of people with intellectual disability. This is a rela-
tively under-represented patient group in clinical studies and it
is useful that the results of this study may help inform therapeutic
strategies for this patient cohort particularly likely to require res-
cue medication [17].
Despite the fact that our study focused on a participant popula-
tion with difficult-to-treat epilepsy (as evidenced by the fact that
all participants had emergency treatment plans and had been pre-
scribed rescue medications), a relatively small number of seizures
(less than 10%) led to hospital admissions and ambulance call outs.
It would be unethical to carry out a randomized controlled study to
evaluate how often OMM can stop prolonged seizures and obviate
the involvement of emergency services. However, previous studies
showing that suspected epileptic seizures are one of the common-
est neurological reasons for emergency admission to hospital sug-
gest that the use of OMM had a significant effect on emergency
healthcare usage in the population studied here [18,19]. Our obser-
vations were based on data from a single recent episode of seizure
where OMMwas used as rescue medication. Further studies on the
use of OMM as rescue medication for adults with epilepsy would
be of interest to assess its impact on healthcare resource use
[20,21].
5. Conclusion
The results of this study show that a 10-mg dose of oromucosal
midazolam maleate is used most often as rescue medication for
adults with epilepsy and is effective when administered in com-
munity settings.
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